DongKoo Bio & Pharma’s (KOSDAQ:006620) Earnings Are Built On Soft Foundations

Solid profit numbers didn’t seem to be enough to please DongKoo Bio & Pharma Co., Ltd.’s (KOSDAQ:006620) shareholders. Our analysis suggests they may be concerned about some underlying details.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Examining Cashflow Against DongKoo Bio & Pharma’s Earnings

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). In plain english, this ratio subtracts FCF from net profit, and divides that number by the company’s average operating assets over that period. The ratio shows us how much a company’s profit exceeds its FCF.

That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. That is not intended to imply we should worry about a positive accrual ratio, but it’s worth noting where the accrual ratio is rather high. That’s because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.

For the year to December 2025, DongKoo Bio & Pharma had an accrual ratio of 0.38. As a general rule, that bodes poorly for future profitability. And indeed, during the period the company didn’t produce any free cash flow whatsoever. Over the last year it actually had negative free cash flow of ₩25b, in contrast to the aforementioned profit of ₩50.3b. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of ₩25b, this year, indicates high risk. Having said that, there is more to the story. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio.

Check out our latest analysis for DongKoo Bio & Pharma

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of DongKoo Bio & Pharma.

The Impact Of Unusual Items On Profit

As it happens, there are a few different things to consider when we look at DongKoo Bio & Pharma’s profit and the last one we’ll mention is ₩39b gain booked as unusual items. While it’s always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that’s exactly what the accounting terminology implies. DongKoo Bio & Pharma had a rather significant contribution from unusual items relative to its profit to December 2025. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

Our Take On DongKoo Bio & Pharma’s Profit Performance

DongKoo Bio & Pharma had a weak accrual ratio, but its profit did receive a boost from unusual items. Considering all this we’d argue DongKoo Bio & Pharma’s profits probably give an overly generous impression of its sustainable level of profitability. In light of this, if you’d like to do more analysis on the company, it’s vital to be informed of the risks involved. Case in point: We’ve spotted 3 warning signs for DongKoo Bio & Pharma you should be mindful of and 2 of these are concerning.

In this article we’ve looked at a number of factors that can impair the utility of profit numbers, and we’ve come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.